Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 5/2007

01-06-2007 | Original Paper

Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis

Auteurs: Laura C. Plantinga, Nancy E. Fink, Bernard G. Jaar, I-Chan Huang, Albert W. Wu, Klemens B. Meyer, Neil R. Powe

Gepubliceerd in: Quality of Life Research | Uitgave 5/2007

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Objective

We sought to examine the relation between meeting or exceeding the current minimum guideline for hemoglobin (11 g/dl) in dialysis patients and generic and disease-specific QOL scores at 1 year.

Methods

In 438 incident hemodialysis patients from a national prospective cohort study, we used regression models to predict QOL score (all scaled 0–100) at 1 year using 6-month values of hemoglobin, adjusting for potential confounders.

Results

Compared to values <11 g/dl, hemoglobin ≥11 g/dl at 6 months was associated with higher scores for the general domains of physical functioning, role physical, mental health, social functioning, and bodily pain at 1 year; cognitive function, diet restriction, and dialysis access dialysis-specific domain scores were also higher for these patients. Each 1 g/dl greater hemoglobin was also statistically significantly associated with higher QOL scores for most domains. In longitudinal analyses, most of the domains showed that, with each 1 g/dl increase in hemoglobin concentration from baseline to 6 months, QOL score increased significantly over the first year.

Conclusions

Hemodialysis patients who attain higher hemoglobin concentration at 6 months, especially ≥11 g/dl, have better QOL at 1 year, with regard to important physical, mental, social, and cognitive domains.
vorige artikel The usefulness of the EQ-5D in differentiating among persons with major depressive episode and anxiety
volgende artikel The OVIS study: health related quality of life measured by the EORTC QLQ-C30 and -BR23 in German female patients with breast cancer from Schleswig-Holstein
Literatuur
1.
Astor, B. C., Eustace, J. A., Powe, N. R., Klag, M. J., Sadler, J. H., Fink, N. E., & Coresh, J. (2001). Timing of nephrologist referral and arteriovenous access use: the CHOICE Study. American Journal of Kidney Diseases, 38, 494–501.PubMed
2.
Athienites, N. V., Miskulin, D. C., Fernandez, G., Bunnapradist, S., Simon, G., Landa, M., Schmid, C. H., Greenfield, S., Levey, A. S., & Meyer, K. B. (2000). Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease. Seminars in Dialysis, 13, 320–326.PubMedCrossRef
3.
Baiardi, F., Degli, E. E., Cocchi, R., Fabbri, A., Sturani, A., Valpiani, G., & Fusarol, M. (2002). Effects of clinical and individual variables on quality of life in chronic renal failure patients. Journal of Nephrology, 15, 61–67.PubMed
4.
Berns, J. S. (2005). Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed? Seminars in Dialysis, 18, 22–29.PubMedCrossRef
5.
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998). The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine, 339, 584–590.PubMedCrossRef
6.
Breiterman-White, R. (2005). Functional ability of patients on dialysis: the critical role of anemia. Nephrology Nursing Journal 32, 79–82.PubMed
7.
Centers for Medicare & Medicaid Services (2005) Centers for Medicare & Medicaid Services Claims Monitoring Policy: Erythropoietin/darbepoietin alfa Usage for Beneficiaries with End Stage Renal Disease.
8.
Collins, A. J., Ma, J. Z., Xia, A., & Ebben, J. (1998). Trends in anemia treatment with erythropoietin usage and patient outcomes. American Journal of Kidney Diseases, 32, S133–S141.PubMed
9.
Daugirdas, J. T. (1993). Second-generation logarithmic estimates of single-pool variable volume of Kt/V: an analysis of error. Journal of the American Society of Nephrology, 4, 1204–1213.
10.
Eschbach, J. W. (1993). Erythropoietin is not a cause of access thrombosis. Seminars in Dialysis, 6, 180–184.
11.
Evans, R. W., Rader, B., & Manninen D. L. (1990). The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. The Journal of the American Medical Association, 263, 825–830.CrossRef
12.
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barre, P. E. (1996). The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. American Journal of Kidney Diseases, 28, 53–61.PubMed
13.
Furuland, H., Linde, T., Ahlmen, J., Christensson, A., Strombom, U., & Danielson, B. G. (2003). A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrology, Dialysis, Transplantion, 18, 353–361.CrossRef
14.
Greenfield, S., Apolone, G., McNeil, B. J., & Cleary, P. D. (1993). The importance of coexistent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Medical Care, 31, 141–154.PubMedCrossRef
15.
Gregory, N. (2005). Quality of life in patients on dialysis: benefits of maintaining a hemoglobin of 11 to 12 g/dL. Nephrology Nursing Journal, 32, 307–310.PubMed
16.
Hays, R. D., Farivar, S. S., & Liu, H. (2005). Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD:. J ournal of Chronic Obstructive Pulmonary Disease, 2, 63–67.
17.
Hudis, C. A., Vogel, C. L., Gralow, J. R., & Williams, D. (2005). Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. Clinical Breast Cancer, 6, 132–142.PubMedCrossRef
18.
Kalantar-Zadeh, K., Kopple, J. D., Block, G., & Humphreys, M. H. (2001). Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. Journal of the American Society of Nephrology, 12, 2797–2806.PubMed
19.
Lawrence, I. G., Price, D. E., Howlett, T. A., Harris, K. P., Feehally, J., & Walls, J. (1997). Erythropoietin and sexual dysfunction. Nephrology, Dialysis, Transplantion, 12, 741–747.CrossRef
20.
Lim, V. S. (1987). Reproductive function in patients with renal insufficiency. American Journal of Kidney Diseases, 9:363–367.PubMed
21.
Lin, D. Y., & Wei, L. J. (1989). The robust inference for the Cox proportional hazards model. Journal of the American Statistical Association, 84, 1074–1078.CrossRef
22.
Localio, A. R., Berlin, J. A., Ten, Have, T. R., & Kimmel, S. E. (2001). Adjustments for center in multicenter studies: an overview. Annals of International Medicine, 135, 112–123.
23.
Ma, J. Z., Ebben, J., Xia, H., & Collins, A. J. (1999). Hematocrit level and associated mortality in hemodialysis patients. Journal of the American Society of Nephrology, 10, 610–619.PubMed
24.
Mapes, D. L., Lopes, A. A., Satayathum, S, McCullough, K. P., Goodkin, D. A., Locatelli, F., Fukuhara, S., Young, E. W., Kurokawa, K., Saito, A., Bommer, J., Wolfe, R. A., Held, P. J., & Port, F. K. (2003). Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney International, 64, 339–349.PubMedCrossRef
25.
Miskulin, D. C., Meyer, K. B., Athienites, N. V., Martin, A. A., Terrin, N., Marsh, J. V., Fink, N. E., Coresh, J., Powe, N. R., Klag, M. J., & Levey, A. S. (2000). Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease. American Journal of Kidney Diseases, 39, 324–336.
26.
Miskulin, D. C., Athienites, N. V., Yan, G., Martin, A. A., Ornt, D. B., Kusek, J. W., Meyer, K. B., & Levey, A. S. (2001). Comorbidity assessment using the Index of Coexistent Diseases in a multi-center clinical trial. Kidney International, 60, 1498–1510.PubMedCrossRef
27.
Moreno, F., Sanz-Guajardo, D., Lopez-Gomez, J. M., Jofre, R., & Valderrabano, F. (2000). Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. Journal of the American Society of Nephrology, 11, 335–342.PubMed
28.
Muirhead, N. (1993). Erythropoietin is a cause of access thrombosis. Seminars in Dialysis, 6, 184–188.
29.
National Kidney Foundation (2005). Kidney Disease Outcomes Quality Initiative (KDOQI). Clinical Practice Guidelines. Available at: http://​www.​kidney.​org/​professionals/​kdoqi/​guidelines.​cfm.​ 2005. New York, NY, National Kidney Foundation.
30.
Parfrey, P. S., Foley, R. N., Wittreich, B. H., Sullivan, D. J., Zagari, M. J., & Frei, D. (2005). Double- blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. Journal of the American Society of Nephrology, 16(7), 2180–2189.PubMedCrossRef
31.
Perlman, R. L., Finkelstein, F. O., Liu, L., Roys, E., Kiser, M., Eisele, G., Burrows-Hudson, S., Messana, J. M., Levin, N., Rajagopalan, S., Port, F. K., Wolfe, R. A., & Saran, R. (2005). Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. American Journal of Kidney Diseases, 45, 658–666.PubMedCrossRef
32.
Powe, N. R., Klag, M. J., Sadler, J. H., Anderson, G. F., Bass, E. B., Briggs, W. A., Fink, N. E., Levey, A. S., Levin, N. W., Meyer, K. B., Rubin, H. R., & Wu, A. W. (1996). Choices for healthy outcomes in caring for end stage renal disease. Seminars in Dialysis, 9, 9–11.
33.
Schatell, D., & Witten, B. (2004). Anemia: dialysis patients experiences. Nephrology News & Issues, 18, 49–54.
34.
Semba, R. D., Martin, B. K., Kempen, J. H., Thorne, J. E., & Wu, A. W. (2005). The impact of anemia on energy and physical functioning in individuals with AIDS. Archives of Internal Medicine 165, 2229–2236.PubMedCrossRef
35.
Stivelman, J. C. (2000). Benefits of anaemia treatment on cognitive function. Nephrology, Dialysis, Transplantation, 15(Suppl 3), 29–35.PubMed
36.
Taft, C., Karlsson, J., & Sullivan, M. (2001). Do SF-36 summary component scores accurately summarize subscale scores? Quality of Life Research, 10, 395–404.PubMedCrossRef
37.
Taji, Y., Morimoto, T., Okada, K., Fukuhara, S., Fukui, T., & Kuwahara, T. (2004). Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients. Journal of Nephrology, 17, 537–543.PubMed
38.
Tonelli, M., Winkelmayer, W. C., Jindal, K. K., Owen, W. F., & Manns, B. J. (2003). The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney International, 64, 295–304.PubMedCrossRef
39.
Valderrabano, F. (2000). Quality of life benefits of early anaemia treatment. Nephrology, Dialysis, Transplantation, 15(Suppl 3), 23–28.PubMed
40.
Valderrabano, F., Jofre, R., & Lopez-Gomez, J. M. (2001). Quality of life in end-stage renal disease patients. American Journal of Kidney Disease, 38, 443–464.
41.
Vazquez, I., Valderrabano, F., Jofre, R., Fort, J., Lopez-Gomez, J. M., Moreno, F, & Sanz-Guajardo, D. (2003). Psychosocial factors and quality of life in young hemodialysis patients with low comorbidity. Journal of Nephrology, 16, 886–894.PubMed
42.
Ware, J. E. Jr (1993). SF-36 Health Survey: Manual & Interpretation Guide. Boston, MA: The New England Medical Center Health Institute.
43.
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989). Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. Journal of the American Statistical Association, 84, 1065–1073.CrossRef
44.
Wu, A. W., Fink, N. E., Cagney, K. A., Bass, E. B., Rubin, H. R., Meyer, K. B., Sadler, J. H., & Powe, N. R. (2001). Developing a health-related quality-of-life measure for end-stage renal disease: The CHOICE Health Experience Questionnaire. American Journal of Kidney Diseases, 37, 11–21.PubMed
45.
Xia, H., Ebben, J., Ma, J. Z., & Collins, A. J. (1999). Hematocrit levels and hospitalization risks in hemodialysis patients. Journal of the American Society of Nephrology, 10, 1309–1316.PubMed
46.
Yang, S. C., Kuo, P. W., Wang, J. D., Lin, M. I., & Su, S. (2005). Quality of life and its determinants of hemodialysis patients in Taiwan measured with WHOQOL-BREF(TW). American Journal of Kidney Disorders, 46, 635–641.CrossRef
Metagegevens
Titel
Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis
Auteurs
Laura C. Plantinga
Nancy E. Fink
Bernard G. Jaar
I-Chan Huang
Albert W. Wu
Klemens B. Meyer
Neil R. Powe
Publicatiedatum
01-06-2007
Uitgeverij
Kluwer Academic Publishers
Gepubliceerd in
Quality of Life Research / Uitgave 5/2007
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-007-9176-6

Andere artikelen Uitgave 5/2007

Quality of Life Research 5/2007 Naar de uitgave

Original Paper

Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a US general population survey using Shannon’s indices

Erratum

Health-related quality of life of firefighters and police officers 8.5 years after the air disaster in Amsterdam

Erratum

Issues in conducting cross-cultural research: implementation of an agreed international protocol designed by the WHOQOL Group for the conduct of focus groups eliciting the quality of life of older adults

Original Paper

Field testing of a European quality of life instrument for children and adolescents with chronic conditions: the 37-item DISABKIDS Chronic Generic Module

Original Paper

The OVIS study: health related quality of life measured by the EORTC QLQ-C30 and -BR23 in German female patients with breast cancer from Schleswig-Holstein

Original Paper

The relationship between gender, social support, and health-related quality of life in a community-based study in Washington County, Maryland